Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease
2018
Background
We quantified loss of response (LOR) to vedolizumab (VDZ) in clinical practice and assessed the effectiveness of VDZ dose intensification for managing LOR.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
21
References
30
Citations
NaN
KQI